Final Overall Survival (Os) Analysis of Cou-Aa-302, a Randomized Phase 3 Study of Abiraterone Acetate (Aa) in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts) Without Prior Chemotherapy

New advances in genitourinary cancer: evidence gathered in 2014

“…Aplastic anemia was reported in one patient treated with Ra-223, and it was considered related to treatment. Primary cancers in other organs, identified in two patients treated with Ra-223 and in three treated with placebo, were [46]. COU-AA-302 trial is an international, randomized, double-blind, placebo-controlled phase 3 study that included 1,088 men with metastatic castration-resistant prostate cancer who had not received prior chemotherapy.…”

“…Much of new evidence published last year refers to the study of some of these mechanisms. In chemotherapy-naive patients, PSA responses to abiraterone and enzalutamide have been reported in 62 and 78 % of patients, respectively [44,46], but of those who respond, 80-90 % develop acquired resistance. In the clinic, patterns of response to AR-targeted therapy with enzalutamide included dramatic declines in PSAwith durable radiographic control, an intermediate response characterized by a slowly rising PSA, and a proportion of patients who do not respond [55].…”

Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer

“…They have all shown to prolong overall survival (OS) in patients with mCRPC progressing after docetaxel-based chemotherapy [1][2][3][4]. In addition, AA and ENZ have also achieved OS benefits in chemo-naïve minimally symptomatic patients, in which only one immunotherapy ─sipuleucel-T─ had previously done so [5][6][7]. Still, 10 to 20% of patients are primarily refractory to either AA or ENZ [5,6].…”

“…In addition, AA and ENZ have also achieved OS benefits in chemo-naïve minimally symptomatic patients, in which only one immunotherapy ─sipuleucel-T─ had previously done so [5][6][7]. Still, 10 to 20% of patients are primarily refractory to either AA or ENZ [5,6]. Adequate characterization of those patients would avoid undesirable delays of potentially more successful therapies.…”

Gene BRCA1/2 mutation in prostate cancer patients: clinical administration aspects

“…Клиническая значи-мость более глубокой супрессии уровня тестосте-рона (ни же кастрационного уровня) наглядно продемонст рирована при метастатическом кастра-ционно-резистентном РПЖ. Так, абиратерона аце-тат, показавший улучшение общей выживаемости больных РПЖ по сравнению с плацебо как до, так и после химиотерапии, снижает уровень тестосте-рона в сыворотке крови примерно на 90 % от значе-ний, которые были достигнуты при кастрации, бло-кируя синтез андрогенов в органах-мишенях посредством ингибирования фермента 17-альфа-ги-дроксилазы [12,13].…”